董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Luca Benatti | 男 | Director | 62 | 32.74万美元 | 未持股 | 2023-03-31 |
| Dagmar Rosa Bjorkeson | 女 | Director | 59 | 31.99万美元 | 未持股 | 2023-03-31 |
| Keith Gottesdiener | 男 | Director | 69 | 32.24万美元 | 未持股 | 2023-03-31 |
| Nancy Miller Rich | 女 | Director | 64 | 32.49万美元 | 未持股 | 2023-03-31 |
| Jerome Durso | 男 | Director and President and Chief Executive Officer | 55 | 未披露 | 未持股 | 2023-03-31 |
| Jerome Durso | 男 | Director and President and Chief Executive Officer | 55 | 445.55万美元 | 未持股 | 2023-03-31 |
| Dagmar Rosa Bjorkeson | 女 | Director | 59 | 未披露 | 未持股 | 2023-03-31 |
| Daniel M. Bradbury | 男 | Director | 61 | 32.74万美元 | 未持股 | 2023-03-31 |
| Glenn P. Sblendorio | 男 | Director | 67 | 33.24万美元 | 未持股 | 2023-03-31 |
| Srinivas Akkaraju | 男 | Director | 55 | 31.74万美元 | 未持股 | 2023-03-31 |
| Gino Santini | 男 | Lead Independent Director | 66 | 33.74万美元 | 未持股 | 2023-03-31 |
| Mark Pruzanski | 男 | Director | 55 | 615.47万美元 | 未持股 | 2023-03-31 |
| Paolo Fundaro | 男 | Chairman of the Board | 49 | 34.24万美元 | 未持股 | 2023-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jared Freedberg | 男 | General Counsel | 55 | 131.17万美元 | 未持股 | 2023-03-31 |
| Jerome Durso | 男 | Director and President and Chief Executive Officer | 55 | 未披露 | 未持股 | 2023-03-31 |
| David Ford | 男 | Chief Human Resources Officer | 54 | 191.26万美元 | 未持股 | 2023-03-31 |
| Jerome Durso | 男 | Director and President and Chief Executive Officer | 55 | 445.55万美元 | 未持股 | 2023-03-31 |
| Andrew Saik | 男 | Chief Financial Officer | 54 | 138.77万美元 | 未持股 | 2023-03-31 |
| Andrew Saik | 男 | Chief Financial Officer | 53 | 未披露 | 未持股 | 2023-03-31 |
| M. Michelle Berrey | 女 | President of Research & Development; Chief Medical Officer | 56 | 未披露 | 未持股 | 2023-03-31 |
| Linda Richardson | 女 | Chief Commercial Officer | 59 | 未披露 | 未持股 | 2023-03-31 |
| Jared Freedberg | 男 | General Counsel | 54 | 未披露 | 未持股 | 2023-03-31 |
| Rocco Venezia | 男 | Chief Accounting Officer | 47 | 未披露 | 未持股 | 2023-03-31 |
| M. Michelle Berrey | 女 | President of Research & Development; Chief Medical Officer | 56 | 161.42万美元 | 未持股 | 2023-03-31 |
| Linda Richardson | 女 | Chief Commercial Officer | 59 | 133.68万美元 | 未持股 | 2023-03-31 |
董事简历
中英对照 | 中文 | 英文- Luca Benatti
-
Luca Benatti，他是博士。他担任Intercept Pharmaceuticals, Inc.的董事（2014年以来）。他在生物制药行业有超过25年的经验，也一直担任EryDel S.p.A。（药公司，专门从事药物和诊断制剂的开发）的首席执行官兼董事（2012年6月以来）。从1999年到2012年5月，他曾担任Newron Pharmaceuticals S.p.A。（瑞士交易所上市公司）的创始人兼首席执行官，以及董事会成员。他于2014年3月重新加入Newron公司的董事会，担任外部董事。在他的指导下，Newron公司开发了潜在疗法，以及其最先进化合物沙芬酰胺，最近获得欧洲批准，并在美国监管审查下治疗帕金森病。他也曾与Merck Serono公司、Meiji Seika公司、Zambon公司、Hunter Fleming公司（一个英国的生物科技公司）收购敲定数百万授权协议。他毕业于Milano Genetics Institute，并进行他的博士后训练。他是Assobiotec公司、意大利生物技术协会（the Italian Biotech Association）的董事会成员兼副总裁、Zambon Pharma S.p.A。的科学顾问委员会主席，以及the jury of the European Biotechnica Award的成员。他写过若干科学出版物，并拥有一些专利。
Luca Benatti, Ph.D. has served as a member of Intercept Pharmaceuticals, Inc. board of directors since July 2014. Dr. Benatti has over 25 years of experience in the biopharmaceutical industry and has been serving as the chief executive officer and a director of EryDel S.p.A., a drug delivery company focused on rare diseases, since June 2012. From 1999 until May 2012 Dr. Benatti was the founder and chief executive officer of Newron Pharmaceuticals S.p.A., a company listed on the Swiss Exchange. Under his guidance, Newron developed a pipeline of potential therapies, with its most advanced compound, Xadago, approved in Europe and recently approved in the United States for the treatment of Parkinson's disease. He also was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon Pharma S.p.A., and in the acquisition of Hunter Fleming, a U.K.-based biotechnology company. From 1985 to 1998 he held various R&D positions at Farmitalia, Pharmacia and Pharmacia & Upjohn. Dr. Benatti graduated from and performed his post-doctoral training at Milano Genetics Institute. He serves as director on the board of Newron SIX: NWRN, as chairman of the scientific advisory board of Zambon, as chairman of the Italian Angels for Biotech association, as a member of the board of Assobiotec, the Italian Biotech Association, and member of the jury of the European Biotechnica Award. He has authored several scientific publications and holds a number of patents. - Luca Benatti，他是博士。他担任Intercept Pharmaceuticals, Inc.的董事（2014年以来）。他在生物制药行业有超过25年的经验，也一直担任EryDel S.p.A。（药公司，专门从事药物和诊断制剂的开发）的首席执行官兼董事（2012年6月以来）。从1999年到2012年5月，他曾担任Newron Pharmaceuticals S.p.A。（瑞士交易所上市公司）的创始人兼首席执行官，以及董事会成员。他于2014年3月重新加入Newron公司的董事会，担任外部董事。在他的指导下，Newron公司开发了潜在疗法，以及其最先进化合物沙芬酰胺，最近获得欧洲批准，并在美国监管审查下治疗帕金森病。他也曾与Merck Serono公司、Meiji Seika公司、Zambon公司、Hunter Fleming公司（一个英国的生物科技公司）收购敲定数百万授权协议。他毕业于Milano Genetics Institute，并进行他的博士后训练。他是Assobiotec公司、意大利生物技术协会（the Italian Biotech Association）的董事会成员兼副总裁、Zambon Pharma S.p.A。的科学顾问委员会主席，以及the jury of the European Biotechnica Award的成员。他写过若干科学出版物，并拥有一些专利。
- Luca Benatti, Ph.D. has served as a member of Intercept Pharmaceuticals, Inc. board of directors since July 2014. Dr. Benatti has over 25 years of experience in the biopharmaceutical industry and has been serving as the chief executive officer and a director of EryDel S.p.A., a drug delivery company focused on rare diseases, since June 2012. From 1999 until May 2012 Dr. Benatti was the founder and chief executive officer of Newron Pharmaceuticals S.p.A., a company listed on the Swiss Exchange. Under his guidance, Newron developed a pipeline of potential therapies, with its most advanced compound, Xadago, approved in Europe and recently approved in the United States for the treatment of Parkinson's disease. He also was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon Pharma S.p.A., and in the acquisition of Hunter Fleming, a U.K.-based biotechnology company. From 1985 to 1998 he held various R&D positions at Farmitalia, Pharmacia and Pharmacia & Upjohn. Dr. Benatti graduated from and performed his post-doctoral training at Milano Genetics Institute. He serves as director on the board of Newron SIX: NWRN, as chairman of the scientific advisory board of Zambon, as chairman of the Italian Angels for Biotech association, as a member of the board of Assobiotec, the Italian Biotech Association, and member of the jury of the European Biotechnica Award. He has authored several scientific publications and holds a number of patents.
- Dagmar Rosa Bjorkeson
-
Dagmar Rosa Bjorkeson，预计将在公司完成分离之际担任Biosimilars执行副总裁和总裁。 Rosa-Bjorkeson有着20多年的行业经验，2014年加入Baxter担任生物仿制制药项目领导人。在此之前，她在Novartis Pharmaceuticals 任职17年多，担任多个职位，最近的职位是担任副总裁和Novartis Pharmaceuticals 主管。之前她曾在Novartis担任其他副总裁职位，包括担任瑞士地区主管，以及专注于销售和品牌的领导职位。加入Novartis之前，她在Forest Pharmaceutical, Ferguson Advertising 和 Hoechst-Roussell Pharmaceuticals担任多个与销售有关的职位。
Dagmar Rosa Bjorkeson,has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development and operational execution. She has led multiple successful product launches, including Gilenya for multiple sclerosis and Elidel for atopic eczema. During her 17 years at Novartis, Ms. Rosa-Bjorkeson was Vice President and Head of its Multiple Sclerosis Business Unit; Vice President, Business Development and Licensing in the United States; and Country Head and President for Novartis Sweden. More recently, she served as Executive Vice President and President, Biosimilars, at Baxalta, now a wholly owned subsidiary of Takeda Pharmaceutical Company. Ms. Rosa-Bjorkeson was also Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals. She holds an MBA in Marketing, an MS in Chemistry and a BS, Chemistry from the University of Texas. - Dagmar Rosa Bjorkeson，预计将在公司完成分离之际担任Biosimilars执行副总裁和总裁。 Rosa-Bjorkeson有着20多年的行业经验，2014年加入Baxter担任生物仿制制药项目领导人。在此之前，她在Novartis Pharmaceuticals 任职17年多，担任多个职位，最近的职位是担任副总裁和Novartis Pharmaceuticals 主管。之前她曾在Novartis担任其他副总裁职位，包括担任瑞士地区主管，以及专注于销售和品牌的领导职位。加入Novartis之前，她在Forest Pharmaceutical, Ferguson Advertising 和 Hoechst-Roussell Pharmaceuticals担任多个与销售有关的职位。
- Dagmar Rosa Bjorkeson,has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development and operational execution. She has led multiple successful product launches, including Gilenya for multiple sclerosis and Elidel for atopic eczema. During her 17 years at Novartis, Ms. Rosa-Bjorkeson was Vice President and Head of its Multiple Sclerosis Business Unit; Vice President, Business Development and Licensing in the United States; and Country Head and President for Novartis Sweden. More recently, she served as Executive Vice President and President, Biosimilars, at Baxalta, now a wholly owned subsidiary of Takeda Pharmaceutical Company. Ms. Rosa-Bjorkeson was also Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals. She holds an MBA in Marketing, an MS in Chemistry and a BS, Chemistry from the University of Texas.
- Keith Gottesdiener
-
Keith Gottesdiener，医学博士，自2016年7月起担任我们的董事会成员。Keith Gottesdiener博士自2011年10月以来一直担任Rhythm Holding Co.，LLC的首席执行官兼董事会成员，该公司是一家控股公司，拥有一家子公司Rhythm Pharmaceuticals，他也是该公司的首席执行官兼董事会成员。他在Merck Research Laboratories工作16年后加入Rhythm。Gottesdiener博士于1995年加入默克早期临床开发，帮助将化合物从板凳过渡到床边，并通过概念验证。他曾担任越来越重要的职务，最终领导Merck公司的早期临床开发（从2001年到2006年初），涉及所有治疗领域。从2006年到2011年，他曾担任Merck&8217；s Late Clinical Development Organization的领导人，首先通过关键试验、注册和生命周期管理监管Merck&8217；s传染病和疫苗产品的开发，包括Gardasiltm HPV疫苗、RotateQTM（轮状病毒疫苗）、ZostavaxTM（带状病毒疫苗）和iSentresSTM（艾滋病毒整合酶抑制剂）等。2008年，Gottesdiener博士被任命为后期治疗小组负责人，并在该职位上领导Merck&8217；在所有治疗领域的后期临床开发工作（从2期到专利到期）。2009年Merck&8217；与Schering Plough合并后，他继续担任后期开发联席主管。Gottesdiener在Harvard College获得学士学位，在University of Pennsylvania获得医学博士学位。他在Brigham and Women&8217；s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children&8217；s Hospital Programs完成住院医师和研究金。在获得奖学金后，Gottesdiener博士在Dana Farber癌症研究所Jack Strominger博士的实验室进行博士后研究，致力于T细胞受体的分子免疫学。1986年他加入Columbia University担任助理教授，利用NIH RO-1Funding启动了一个独立的研究实验室，专注于基因转录，1995年他离开加入Merck时是医学临床副教授。
Keith Gottesdiener has served as Prime Medicine, Inc. Chief Executive Officer and a member of Prime Medicine, Inc. board of directors since July 2020. Prior to that, from October 2011 until March 2020 Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Gottesdiener joined Rhythm after 16 years at Merck Research Laboratories, where he held positions of increasing responsibility, including serving as a leader of Merck's late clinical development organization from 2006 to 2011 and leading Merck's early clinical development across all therapeutic areas from 2001 through early 2006. Dr. Gottesdiener currently serves as a director of Intercept Pharmaceuticals, Inc., and Cardurion Pharmaceuticals, both biotechnology companies. He received his M.D. from the University of Pennsylvania and his B.A. in Applied Mathematics from Harvard College. - Keith Gottesdiener，医学博士，自2016年7月起担任我们的董事会成员。Keith Gottesdiener博士自2011年10月以来一直担任Rhythm Holding Co.，LLC的首席执行官兼董事会成员，该公司是一家控股公司，拥有一家子公司Rhythm Pharmaceuticals，他也是该公司的首席执行官兼董事会成员。他在Merck Research Laboratories工作16年后加入Rhythm。Gottesdiener博士于1995年加入默克早期临床开发，帮助将化合物从板凳过渡到床边，并通过概念验证。他曾担任越来越重要的职务，最终领导Merck公司的早期临床开发（从2001年到2006年初），涉及所有治疗领域。从2006年到2011年，他曾担任Merck&8217；s Late Clinical Development Organization的领导人，首先通过关键试验、注册和生命周期管理监管Merck&8217；s传染病和疫苗产品的开发，包括Gardasiltm HPV疫苗、RotateQTM（轮状病毒疫苗）、ZostavaxTM（带状病毒疫苗）和iSentresSTM（艾滋病毒整合酶抑制剂）等。2008年，Gottesdiener博士被任命为后期治疗小组负责人，并在该职位上领导Merck&8217；在所有治疗领域的后期临床开发工作（从2期到专利到期）。2009年Merck&8217；与Schering Plough合并后，他继续担任后期开发联席主管。Gottesdiener在Harvard College获得学士学位，在University of Pennsylvania获得医学博士学位。他在Brigham and Women&8217；s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children&8217；s Hospital Programs完成住院医师和研究金。在获得奖学金后，Gottesdiener博士在Dana Farber癌症研究所Jack Strominger博士的实验室进行博士后研究，致力于T细胞受体的分子免疫学。1986年他加入Columbia University担任助理教授，利用NIH RO-1Funding启动了一个独立的研究实验室，专注于基因转录，1995年他离开加入Merck时是医学临床副教授。
- Keith Gottesdiener has served as Prime Medicine, Inc. Chief Executive Officer and a member of Prime Medicine, Inc. board of directors since July 2020. Prior to that, from October 2011 until March 2020 Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Gottesdiener joined Rhythm after 16 years at Merck Research Laboratories, where he held positions of increasing responsibility, including serving as a leader of Merck's late clinical development organization from 2006 to 2011 and leading Merck's early clinical development across all therapeutic areas from 2001 through early 2006. Dr. Gottesdiener currently serves as a director of Intercept Pharmaceuticals, Inc., and Cardurion Pharmaceuticals, both biotechnology companies. He received his M.D. from the University of Pennsylvania and his B.A. in Applied Mathematics from Harvard College.
- Nancy Miller Rich
-
Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前，米勒-里奇曾在默克制药公司担任过多个领导职务，在两家公司合并之前，她曾在Schering-PloughCorporation担任过多个领导职务，包括最近担任高级副总裁，全球人类健康业务开发与许可部门的职务，2013年11月至2017年9月提供战略和商业支持，2007年1月至2013年11月担任集团Vice President，Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前，Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug，Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员，例如自2018年4月以来担任InterceptPharmaceuticals，Inc.董事，自2020年1月以来担任AldeyraTherapeutics，Inc.董事，自2020年10月以来担任KadmonHoldings，Inc.董事。她于1981年获得纽约伊萨卡学院（Ithaca College）的工商管理营销本科学位。
Nancy Miller Rich,has been a member of Aldeyra Therapeutics, Inc. Board since January 2020. She is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served as Senior Vice-President, Global Human Health Business Development & Licensing, Strategy and Commercial Support at Merck Pharmaceuticals. At Merck, Ms. Miller-Rich had direct P&L involvement in the $38 billion pharmaceutical division and closed approximately 300 deals producing $10 billion of value creation. Prior to Merck, she worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and 4D Molecular Therapeutics, Inc., and previously served as a director of Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York. - Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前，米勒-里奇曾在默克制药公司担任过多个领导职务，在两家公司合并之前，她曾在Schering-PloughCorporation担任过多个领导职务，包括最近担任高级副总裁，全球人类健康业务开发与许可部门的职务，2013年11月至2017年9月提供战略和商业支持，2007年1月至2013年11月担任集团Vice President，Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前，Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug，Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员，例如自2018年4月以来担任InterceptPharmaceuticals，Inc.董事，自2020年1月以来担任AldeyraTherapeutics，Inc.董事，自2020年10月以来担任KadmonHoldings，Inc.董事。她于1981年获得纽约伊萨卡学院（Ithaca College）的工商管理营销本科学位。
- Nancy Miller Rich,has been a member of Aldeyra Therapeutics, Inc. Board since January 2020. She is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served as Senior Vice-President, Global Human Health Business Development & Licensing, Strategy and Commercial Support at Merck Pharmaceuticals. At Merck, Ms. Miller-Rich had direct P&L involvement in the $38 billion pharmaceutical division and closed approximately 300 deals producing $10 billion of value creation. Prior to Merck, she worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and 4D Molecular Therapeutics, Inc., and previously served as a director of Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
- Jerome Durso
-
Jerome Durso自2017年2月起担任我们的首席运营官。在加入公司之前，Durso先生于2015年9月至2017年2月担任生物制药行业顾问。杜尔索先生的大部分职业生涯都在赛诺菲（Sanofi）度过，赛诺菲是一家全球性制药公司，他最近于2011年6月至2015年4月担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。杜索先生在圣母大学获得市场营销学士学位。
Jerome Durso has served as our Chief Operating Officer since February 2017. Prior to joining the Company, Mr. Durso served as a consultant to the biopharmaceutical industry from September 2015 to February 2017. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as Senior Vice President, Chief Commercial Officer of the Global Diabetes Division from June 2011 to April 2015. From 2010 to 2011 Mr. Durso was Senior Vice President, Chief Commercial Officer of Sanofi’s U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso earned his bachelor’s degree in marketing from the University of Notre Dame. - Jerome Durso自2017年2月起担任我们的首席运营官。在加入公司之前，Durso先生于2015年9月至2017年2月担任生物制药行业顾问。杜尔索先生的大部分职业生涯都在赛诺菲（Sanofi）度过，赛诺菲是一家全球性制药公司，他最近于2011年6月至2015年4月担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。杜索先生在圣母大学获得市场营销学士学位。
- Jerome Durso has served as our Chief Operating Officer since February 2017. Prior to joining the Company, Mr. Durso served as a consultant to the biopharmaceutical industry from September 2015 to February 2017. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as Senior Vice President, Chief Commercial Officer of the Global Diabetes Division from June 2011 to April 2015. From 2010 to 2011 Mr. Durso was Senior Vice President, Chief Commercial Officer of Sanofi’s U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso earned his bachelor’s degree in marketing from the University of Notre Dame.
- Jerome Durso
-
JeromeB.Durso自2017年2月起担任我们的首席运营官。他拥有近25年的在美国和国外的生命科学公司建立和领导商业和业务运营的经验。杜尔索的大部分职业生涯都在赛诺菲（Sanofi）度过。赛诺菲是一家全球性制药公司，他最近于2011年至2015年担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。Durso先生目前担任新泽西州萨默维尔Robert Wood Johnson University Hospital Somerset的顾问委员会成员。Durso先生在圣母大学（University of Notre Dame）获得营销学士学位。
Jerome Durso has served as Intercept Pharmaceuticals, Inc. chief operating officer since February 2017. He has nearly 25 years of experience in building and leading commercial and business operations at life sciences companies both in the United States and abroad. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as senior vice president, chief commercial officer of the global diabetes division from 2011 through 2015. From 2010 to 2011 Mr. Durso was senior vice president, chief commercial officer of Sanofi's U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso currently serves as an advisory board member of the Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey. Mr. Durso earned his bachelor degree in marketing from the University of Notre Dame. - JeromeB.Durso自2017年2月起担任我们的首席运营官。他拥有近25年的在美国和国外的生命科学公司建立和领导商业和业务运营的经验。杜尔索的大部分职业生涯都在赛诺菲（Sanofi）度过。赛诺菲是一家全球性制药公司，他最近于2011年至2015年担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。Durso先生目前担任新泽西州萨默维尔Robert Wood Johnson University Hospital Somerset的顾问委员会成员。Durso先生在圣母大学（University of Notre Dame）获得营销学士学位。
- Jerome Durso has served as Intercept Pharmaceuticals, Inc. chief operating officer since February 2017. He has nearly 25 years of experience in building and leading commercial and business operations at life sciences companies both in the United States and abroad. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as senior vice president, chief commercial officer of the global diabetes division from 2011 through 2015. From 2010 to 2011 Mr. Durso was senior vice president, chief commercial officer of Sanofi's U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso currently serves as an advisory board member of the Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey. Mr. Durso earned his bachelor degree in marketing from the University of Notre Dame.
- Dagmar Rosa Bjorkeson
-
Dagmar Rosa Bjorkeson，自2021年4月起担任Intercept Pharmaceuticals, Inc.董事会成员。她在制药行业拥有超过25年的全球经验，包括在企业和产品战略、市场开发和运营执行方面担任行政领导职务。自2020年以来，她一直担任细胞药物上市公司Mesoblast Limited的首席运营官。2017年至2019年，她任职于马林克罗制药，担任执行副总裁兼首席战略与发展官，负责企业和治疗领域战略、业务发展、新产品商业化，还曾担任新产品商业化高级副总裁。2014年至2016年，她在Baxalta（现为武田制药公司的全资子公司）担任生物仿制药执行副总裁兼总裁，在那里她制定了生物仿制药战略，管理从百特国际分拆后的工作，并监督一个完全整合的部门，包括项目管理、研究、临床开发、制造、商业化和业务发展。从1997年到2014年，她在诺华担任过越来越多的职务，包括副总裁兼多发性硬化症业务部门负责人；美国业务发展和许可副总裁；美国呼吸系统副总裁；诺华瑞典公司国家负责人兼总裁。在诺华的17年里，Rosa-Bjorkeson女士的经历跨越了销售、市场营销、一般管理和国家运营。她领导了多个成功的产品发布，包括诺华公司用于多发性硬化症的Gilenya 。自2019年12月以来，她一直在Xencor, Inc.的董事会任职。她还在私营公司Red Nucleus的董事会任职，并在新泽西城市大学基金会和Deirdre's House的非营利董事会任职。Rosa-Bjorkeson女士在得克萨斯大学奥斯汀分校获得了工商管理硕士学位、化学硕士学位和化学学士学位。
Dagmar Rosa Bjorkeson,has served as a member of Intercept Pharmaceuticals, Inc. Board since April 2021. She has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development, and operational execution. Since 2020, she has been the Chief Operating Officer of Mesoblast Limited, a publicly traded cellular medicine company. From 2017 to 2019, she worked at Mallinckrodt Pharmaceuticals, where she was Executive Vice President and Chief Strategy and Development Officer, responsible for corporate and therapeutic area strategy, business development, and new product commercialization, and also served as Senior Vice President of new product commercialization. From 2014 to 2016, she was Executive Vice President and President, Biosimilars, at Baxalta (now a wholly owned subsidiary of Takeda Pharmaceutical Company), where she developed a biosimilars strategy, managed post spin-off efforts from Baxter International, and oversaw a fully integrated unit including program management, research, clinical development, manufacturing, commercialization and business development. From 1997 to 2014, she held various roles of increasing responsibility at Novartis, including Vice President and Head of its multiple sclerosis business unit; Vice President, Business Development and Licensing in the United States; Vice President, Respiratory in the United States; and Country Head and President for Novartis Sweden. Throughout her 17 years at Novartis, Ms. Rosa-Bjorkeson's experience spanned sales, marketing, general management, and country operations. She has led multiple successful product launches, including Gilenya for multiple sclerosis at Novartis. Since December 2019, she has served on the board of directors of Xencor, Inc. She also serves on the board of private company Red Nucleus, and on the non-profit boards of the New Jersey City University Foundation and Deirdre's House. Ms. Rosa-Bjorkeson earned an M.B.A., an M.S. in chemistry, and a B.S. in chemistry from the University of Texas, Austin. - Dagmar Rosa Bjorkeson，自2021年4月起担任Intercept Pharmaceuticals, Inc.董事会成员。她在制药行业拥有超过25年的全球经验，包括在企业和产品战略、市场开发和运营执行方面担任行政领导职务。自2020年以来，她一直担任细胞药物上市公司Mesoblast Limited的首席运营官。2017年至2019年，她任职于马林克罗制药，担任执行副总裁兼首席战略与发展官，负责企业和治疗领域战略、业务发展、新产品商业化，还曾担任新产品商业化高级副总裁。2014年至2016年，她在Baxalta（现为武田制药公司的全资子公司）担任生物仿制药执行副总裁兼总裁，在那里她制定了生物仿制药战略，管理从百特国际分拆后的工作，并监督一个完全整合的部门，包括项目管理、研究、临床开发、制造、商业化和业务发展。从1997年到2014年，她在诺华担任过越来越多的职务，包括副总裁兼多发性硬化症业务部门负责人；美国业务发展和许可副总裁；美国呼吸系统副总裁；诺华瑞典公司国家负责人兼总裁。在诺华的17年里，Rosa-Bjorkeson女士的经历跨越了销售、市场营销、一般管理和国家运营。她领导了多个成功的产品发布，包括诺华公司用于多发性硬化症的Gilenya 。自2019年12月以来，她一直在Xencor, Inc.的董事会任职。她还在私营公司Red Nucleus的董事会任职，并在新泽西城市大学基金会和Deirdre's House的非营利董事会任职。Rosa-Bjorkeson女士在得克萨斯大学奥斯汀分校获得了工商管理硕士学位、化学硕士学位和化学学士学位。
- Dagmar Rosa Bjorkeson,has served as a member of Intercept Pharmaceuticals, Inc. Board since April 2021. She has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development, and operational execution. Since 2020, she has been the Chief Operating Officer of Mesoblast Limited, a publicly traded cellular medicine company. From 2017 to 2019, she worked at Mallinckrodt Pharmaceuticals, where she was Executive Vice President and Chief Strategy and Development Officer, responsible for corporate and therapeutic area strategy, business development, and new product commercialization, and also served as Senior Vice President of new product commercialization. From 2014 to 2016, she was Executive Vice President and President, Biosimilars, at Baxalta (now a wholly owned subsidiary of Takeda Pharmaceutical Company), where she developed a biosimilars strategy, managed post spin-off efforts from Baxter International, and oversaw a fully integrated unit including program management, research, clinical development, manufacturing, commercialization and business development. From 1997 to 2014, she held various roles of increasing responsibility at Novartis, including Vice President and Head of its multiple sclerosis business unit; Vice President, Business Development and Licensing in the United States; Vice President, Respiratory in the United States; and Country Head and President for Novartis Sweden. Throughout her 17 years at Novartis, Ms. Rosa-Bjorkeson's experience spanned sales, marketing, general management, and country operations. She has led multiple successful product launches, including Gilenya for multiple sclerosis at Novartis. Since December 2019, she has served on the board of directors of Xencor, Inc. She also serves on the board of private company Red Nucleus, and on the non-profit boards of the New Jersey City University Foundation and Deirdre's House. Ms. Rosa-Bjorkeson earned an M.B.A., an M.S. in chemistry, and a B.S. in chemistry from the University of Texas, Austin.
- Daniel M. Bradbury
-
Daniel M. Bradbury，自2020年1月起担任董事会执行主席，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任首席执行官。Bradbury先生是Equillium的联合创始人，并于2017年3月至2018年6月担任总裁。他是BioBrit， LLC（生命科学咨询和投资公司）的创始人和管理成员（2012年9月以来）。2007年3月至2012年8月Amylin被百时美施贵宝公司（Bristol-Myers Squibb company）收购，他担任Amylin Pharmaceuticals， Inc.（一家上市的生物制药公司）的总裁、首席执行官和董事。Bradbury先生自2019年7月起担任Castle Biosciences， Inc 。的董事会成员，他还担任薪酬委员会成员和董事会主席。他自2019年1月起担任Biocon Biologics Ltd.的董事会成员，并担任审计委员会成员。他自2024年3月起担任Vivani Medical， Inc.的董事会成员，在那里他还担任审计委员会成员。此外，他还担任许多私人公司的董事会成员。他曾担任Intercept Pharmaceuticals， Inc.（一家上市的生物技术公司）的董事会成员（从2016年到2023年）；Biocon Ltd.，一家上市的生物制药公司，从2013年到2022年；concept Therapeutics Incorporated，一家上市的生物技术公司，从2012年到2019年；Geron Corporation，一家上市的生物技术公司，从2012年到2019年；Illumina, Inc.（一家上市的生物技术公司），从2004年到2017年；Panacea Acquisition Corporation（一家上市的特殊目的收购公司），从2020年到2021年。他持有Nottingham大学的药学学士学位，以及Harrow and Ealing Colleges of Higher Education的管理学文凭。
Daniel M. Bradbury,has served as the Executive Chairman of Board since January 2020 and has been a member of Board since March 2017. He served as Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC ("BioBrit"), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury has served on the board of directors of Castle Biosciences, Inc since July 2019, where he also serves on the compensation committee and as chairman of the board. He has served on the board of directors of Biocon Biologics Ltd. since January 2019, where he also serves on the audit committee. He has served on the board of directors of Vivani Medical, Inc. since March 2024, where he also serves on the audit committee.Additionally, Mr. Bradbury serves on the boards of many private companies. Mr. Bradbury previously served on the boards of directors of Intercept Pharmaceuticals, Inc., a publicly-held biotechnology company, from 2016 to 2023; Biocon Ltd., a publicly-held biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Panacea Acquisition Corporation, a publicly-held special purpose acquisition company, from 2020 to 2021. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. - Daniel M. Bradbury，自2020年1月起担任董事会执行主席，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任首席执行官。Bradbury先生是Equillium的联合创始人，并于2017年3月至2018年6月担任总裁。他是BioBrit， LLC（生命科学咨询和投资公司）的创始人和管理成员（2012年9月以来）。2007年3月至2012年8月Amylin被百时美施贵宝公司（Bristol-Myers Squibb company）收购，他担任Amylin Pharmaceuticals， Inc.（一家上市的生物制药公司）的总裁、首席执行官和董事。Bradbury先生自2019年7月起担任Castle Biosciences， Inc 。的董事会成员，他还担任薪酬委员会成员和董事会主席。他自2019年1月起担任Biocon Biologics Ltd.的董事会成员，并担任审计委员会成员。他自2024年3月起担任Vivani Medical， Inc.的董事会成员，在那里他还担任审计委员会成员。此外，他还担任许多私人公司的董事会成员。他曾担任Intercept Pharmaceuticals， Inc.（一家上市的生物技术公司）的董事会成员（从2016年到2023年）；Biocon Ltd.，一家上市的生物制药公司，从2013年到2022年；concept Therapeutics Incorporated，一家上市的生物技术公司，从2012年到2019年；Geron Corporation，一家上市的生物技术公司，从2012年到2019年；Illumina, Inc.（一家上市的生物技术公司），从2004年到2017年；Panacea Acquisition Corporation（一家上市的特殊目的收购公司），从2020年到2021年。他持有Nottingham大学的药学学士学位，以及Harrow and Ealing Colleges of Higher Education的管理学文凭。
- Daniel M. Bradbury,has served as the Executive Chairman of Board since January 2020 and has been a member of Board since March 2017. He served as Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC ("BioBrit"), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury has served on the board of directors of Castle Biosciences, Inc since July 2019, where he also serves on the compensation committee and as chairman of the board. He has served on the board of directors of Biocon Biologics Ltd. since January 2019, where he also serves on the audit committee. He has served on the board of directors of Vivani Medical, Inc. since March 2024, where he also serves on the audit committee.Additionally, Mr. Bradbury serves on the boards of many private companies. Mr. Bradbury previously served on the boards of directors of Intercept Pharmaceuticals, Inc., a publicly-held biotechnology company, from 2016 to 2023; Biocon Ltd., a publicly-held biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Panacea Acquisition Corporation, a publicly-held special purpose acquisition company, from 2020 to 2021. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
- Glenn P. Sblendorio
-
Glenn P. Sblendorio自2006年6月起担任Amicus Therapeutics, Inc.的董事会成员。他目前是IVERIC bio, Inc.的首席执行官。NASDAQ: ISEE，前身为Ophthotech Corporation (NASDAQ: OPHT)，他自2017年以来一直担任该职位，并且是IVERIC的董事会成员。加入IVERIC之前，他从2006年3月到2016年3月担任The Medicines Company (NASDAQ: MDCO)的总裁兼首席财务官，并从2011年7月到2015年12月31日担任The Medicines Company的董事会成员。加入The Medicines Company之前，他从2002年2月起担任Eyetech Pharmaceuticals, Inc.的执行副总裁兼首席财务官，直到该公司于2005年11月被OSI Pharmaceuticals, Inc.收购。他还担任Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)的董事会成员(审计主席)。他持有Pace University的工商管理硕士学位和Fairleigh Dickinson University的工商管理硕士学位。
Glenn P. Sblendorio has served as a member of the Board of Amicus Therapeutics, Inc. since June 2006. Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. NASDAQ: ISEE, formerly Ophthotech Corporation (NASDAQ: OPHT), a position that he has held since 2017 and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University. - Glenn P. Sblendorio自2006年6月起担任Amicus Therapeutics, Inc.的董事会成员。他目前是IVERIC bio, Inc.的首席执行官。NASDAQ: ISEE，前身为Ophthotech Corporation (NASDAQ: OPHT)，他自2017年以来一直担任该职位，并且是IVERIC的董事会成员。加入IVERIC之前，他从2006年3月到2016年3月担任The Medicines Company (NASDAQ: MDCO)的总裁兼首席财务官，并从2011年7月到2015年12月31日担任The Medicines Company的董事会成员。加入The Medicines Company之前，他从2002年2月起担任Eyetech Pharmaceuticals, Inc.的执行副总裁兼首席财务官，直到该公司于2005年11月被OSI Pharmaceuticals, Inc.收购。他还担任Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)的董事会成员(审计主席)。他持有Pace University的工商管理硕士学位和Fairleigh Dickinson University的工商管理硕士学位。
- Glenn P. Sblendorio has served as a member of the Board of Amicus Therapeutics, Inc. since June 2006. Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. NASDAQ: ISEE, formerly Ophthotech Corporation (NASDAQ: OPHT), a position that he has held since 2017 and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.
- Srinivas Akkaraju
-
Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
Srinivas Akkaraju,has served as a member of Alumis Inc. board of directors since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., and Syros Pharmaceuticals, Inc., and numerous private biopharmaceutical companies. During the past five years, he served as a director of Chinook Therapeutics, Inc., Jiya Acquisition Corp., Aravive, Inc. (formerly Versartis, Inc.), Intercept Pharmaceuticals, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University. - Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
- Srinivas Akkaraju,has served as a member of Alumis Inc. board of directors since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., and Syros Pharmaceuticals, Inc., and numerous private biopharmaceutical companies. During the past five years, he served as a director of Chinook Therapeutics, Inc., Jiya Acquisition Corp., Aravive, Inc. (formerly Versartis, Inc.), Intercept Pharmaceuticals, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.
- Gino Santini
-
Gino Santini，自2012年3月起在董事会任职。目前，他在 AMAG Pharmaceuticals有限公司和Allena Pharmaceuticals有限公司董事会任职，且从Eli Lilly and Company（Lilly）退休，在此他工作了30年之久。在Lilly的任期内，他担任了责任越来越大的职务，包括许多国际地区的经理、女性健康特许的总裁，以及美国运营总裁。他在Lilly担任公司执行委员会董事及企业战略和业务发展高级副总裁。他精通四门语言，且持有博洛尼亚大学（ the University of Bologna）机械工程学士学位和罗切斯特大学（ the University of Rochester）工商管理硕士学位。
Gino Santini,currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., both of which are public biopharma companies. Mr. Santini also serves on the boards of directors of Artax Biopharma Inc. and Enalare Therapeutics, Inc., each a private biopharma company, and is retired from a distinguished career with Eli Lilly and Company. He served as chairman of the board of directors of AMAG Pharmaceuticals, Inc., previously a public biopharma company, from February 2012 until November 2020, when AMAG was acquired by Covis Group S. à r.l., and on the board of directors of Allena Pharmaceuticals, Inc., a public biopharma company, from February 2012 until September 2022. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master of business administration degree from the University of Rochester. - Gino Santini，自2012年3月起在董事会任职。目前，他在 AMAG Pharmaceuticals有限公司和Allena Pharmaceuticals有限公司董事会任职，且从Eli Lilly and Company（Lilly）退休，在此他工作了30年之久。在Lilly的任期内，他担任了责任越来越大的职务，包括许多国际地区的经理、女性健康特许的总裁，以及美国运营总裁。他在Lilly担任公司执行委员会董事及企业战略和业务发展高级副总裁。他精通四门语言，且持有博洛尼亚大学（ the University of Bologna）机械工程学士学位和罗切斯特大学（ the University of Rochester）工商管理硕士学位。
- Gino Santini,currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., both of which are public biopharma companies. Mr. Santini also serves on the boards of directors of Artax Biopharma Inc. and Enalare Therapeutics, Inc., each a private biopharma company, and is retired from a distinguished career with Eli Lilly and Company. He served as chairman of the board of directors of AMAG Pharmaceuticals, Inc., previously a public biopharma company, from February 2012 until November 2020, when AMAG was acquired by Covis Group S. à r.l., and on the board of directors of Allena Pharmaceuticals, Inc., a public biopharma company, from February 2012 until September 2022. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master of business administration degree from the University of Rochester.
- Mark Pruzanski
-
Mark Pruzanski，医学博士，是Intercept Pharmaceuticals, Inc.的联合成立者，自2002年公司成立以来担任Intercept Pharmaceuticals, Inc.的首席执行官和总裁，以及公司董事。他有着超过15年的生命科学公司管理、风险资本和战略咨询方面的经验。Pruzanski博士早前曾是Apple Tree Partners（他于1999年联合成立的早期阶段生命科学风险资本企业）的风险投资合伙人。在那之前，他曾是Oak Investment Partners的常驻企业家。Pruzanski博士获得了安大略McMaster University的医学博士学位， 意大利博洛尼亚和华盛顿特区the Johns Hopkins University School of Advanced International Studies的国际事务硕士学位，魁北克蒙特利尔McGill University的学士学位。他目前担任 Emerging Company Section of the Biotechnology Industry Association BIO 和 the Foundation for the Defense of Democracies（华盛顿特区的一个智库）的董事。Pruzanski博士是大量科学出版物的合著人，以及关于候选人和科学发现的几项专利的发明人。
Mark Pruzanski,has served as a member of Board since September 2018. Dr. Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences sector. Most recently, he served from September 2021 to August 2023, as a member of the board and from April 2022 to September 2023 as Chief Executive Officer of Versanis Bio, a clinical-stage biotechnology company, where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company's acquisition in 2023 by Eli Lilly and Company. Dr. Pruzanski was also a co-founder and member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-held biopharmaceutical company where he served as President and Chief Executive Officer from September 2002 until January 2021. Prior to co-founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early-stage life sciences venture capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co- author of a number of scientific publications and is named as an inventor on several patents. Additionally, Dr. Pruzanski currently serves on the boards of multiple private companies, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor's degree from McGill University in Montreal, Canada. - Mark Pruzanski，医学博士，是Intercept Pharmaceuticals, Inc.的联合成立者，自2002年公司成立以来担任Intercept Pharmaceuticals, Inc.的首席执行官和总裁，以及公司董事。他有着超过15年的生命科学公司管理、风险资本和战略咨询方面的经验。Pruzanski博士早前曾是Apple Tree Partners（他于1999年联合成立的早期阶段生命科学风险资本企业）的风险投资合伙人。在那之前，他曾是Oak Investment Partners的常驻企业家。Pruzanski博士获得了安大略McMaster University的医学博士学位， 意大利博洛尼亚和华盛顿特区the Johns Hopkins University School of Advanced International Studies的国际事务硕士学位，魁北克蒙特利尔McGill University的学士学位。他目前担任 Emerging Company Section of the Biotechnology Industry Association BIO 和 the Foundation for the Defense of Democracies（华盛顿特区的一个智库）的董事。Pruzanski博士是大量科学出版物的合著人，以及关于候选人和科学发现的几项专利的发明人。
- Mark Pruzanski,has served as a member of Board since September 2018. Dr. Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences sector. Most recently, he served from September 2021 to August 2023, as a member of the board and from April 2022 to September 2023 as Chief Executive Officer of Versanis Bio, a clinical-stage biotechnology company, where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company's acquisition in 2023 by Eli Lilly and Company. Dr. Pruzanski was also a co-founder and member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-held biopharmaceutical company where he served as President and Chief Executive Officer from September 2002 until January 2021. Prior to co-founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early-stage life sciences venture capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co- author of a number of scientific publications and is named as an inventor on several patents. Additionally, Dr. Pruzanski currently serves on the boards of multiple private companies, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO), a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor's degree from McGill University in Montreal, Canada.
- Paolo Fundaro
-
Paolo Fundaro，自2006年起担任Intercept Pharmaceuticals, Inc.的董事。Fundaro先生自Genextra 2004年成立起担任其首席财务官。在加入Genextra前，2000年至2004年，Fundaro先生曾担任Fastweb Group的金融和战略计划的主管。早前，他曾在投资银行工作，包括Salomon Smith Barney 现为 Citigroup，以及 Donaldson Lufkin & Jenrette （现为 Credit Suisse）。 Fundaro先生拥有意大利米兰Bocconi University的商业管理学位。
Paolo Fundaro has served as a member of Intercept Pharmaceuticals, Inc. board of directors since 2006 and has acted as Intercept Pharmaceuticals, Inc. chairman since October 2015. Mr. Fundaro has been Genextra's chief financial officer since its inception in 2004. Before joining Genextra, Mr. Fundaro was director of finance and strategic planning for the Fastweb Group from 2000 to 2004. Previously, he worked for investment banks, including Salomon Smith Barney now Citigroup and Donaldson Lufkin & Jenrette (now Credit Suisse). Mr. Fundaro has a degree in Business Management from Bocconi University in Milan, Italy. - Paolo Fundaro，自2006年起担任Intercept Pharmaceuticals, Inc.的董事。Fundaro先生自Genextra 2004年成立起担任其首席财务官。在加入Genextra前，2000年至2004年，Fundaro先生曾担任Fastweb Group的金融和战略计划的主管。早前，他曾在投资银行工作，包括Salomon Smith Barney 现为 Citigroup，以及 Donaldson Lufkin & Jenrette （现为 Credit Suisse）。 Fundaro先生拥有意大利米兰Bocconi University的商业管理学位。
- Paolo Fundaro has served as a member of Intercept Pharmaceuticals, Inc. board of directors since 2006 and has acted as Intercept Pharmaceuticals, Inc. chairman since October 2015. Mr. Fundaro has been Genextra's chief financial officer since its inception in 2004. Before joining Genextra, Mr. Fundaro was director of finance and strategic planning for the Fastweb Group from 2000 to 2004. Previously, he worked for investment banks, including Salomon Smith Barney now Citigroup and Donaldson Lufkin & Jenrette (now Credit Suisse). Mr. Fundaro has a degree in Business Management from Bocconi University in Milan, Italy.
高管简历
中英对照 | 中文 | 英文- Jared Freedberg
Jared Freedberg自2018年9月起担任公司总法律顾问。在加入公司之前，Freedberg先生于2016年12月至2018年9月在Mallinckrodt担任法律Vice President。在加入Mallinckrodt之前，Freedberg先生于2014年11月至2016年11月担任Covance的业务开发和战略Vice President，并于2008年3月至2014年11月担任Covance的助理总法律顾问Vice President。Freedberg先生拥有宾夕法尼亚大学（University of Pennsylvania）的学士学位和杜克大学法学院（Duke University School of Law）的法学博士学位。
Jared Freedberg has served as the Company's General Counsel since September 2018. Prior to joining the Company, Mr. Freedberg was Vice President, Legal at Mallinckrodt from December 2016 to September 2018. Prior to Mallinckrodt, Mr. Freedberg was the Vice President, Business Development and Strategy at Covance from November 2014 to November 2016 and Vice President, Associate General Counsel at Covance from March 2008 to November 2014. Mr. Freedberg holds a B.A. degree from the University of Pennsylvania and a Juris Doctor degree from the Duke University School of Law.- Jared Freedberg自2018年9月起担任公司总法律顾问。在加入公司之前，Freedberg先生于2016年12月至2018年9月在Mallinckrodt担任法律Vice President。在加入Mallinckrodt之前，Freedberg先生于2014年11月至2016年11月担任Covance的业务开发和战略Vice President，并于2008年3月至2014年11月担任Covance的助理总法律顾问Vice President。Freedberg先生拥有宾夕法尼亚大学（University of Pennsylvania）的学士学位和杜克大学法学院（Duke University School of Law）的法学博士学位。
- Jared Freedberg has served as the Company's General Counsel since September 2018. Prior to joining the Company, Mr. Freedberg was Vice President, Legal at Mallinckrodt from December 2016 to September 2018. Prior to Mallinckrodt, Mr. Freedberg was the Vice President, Business Development and Strategy at Covance from November 2014 to November 2016 and Vice President, Associate General Counsel at Covance from March 2008 to November 2014. Mr. Freedberg holds a B.A. degree from the University of Pennsylvania and a Juris Doctor degree from the Duke University School of Law.
- Jerome Durso
Jerome Durso自2017年2月起担任我们的首席运营官。在加入公司之前，Durso先生于2015年9月至2017年2月担任生物制药行业顾问。杜尔索先生的大部分职业生涯都在赛诺菲（Sanofi）度过，赛诺菲是一家全球性制药公司，他最近于2011年6月至2015年4月担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。杜索先生在圣母大学获得市场营销学士学位。
Jerome Durso has served as our Chief Operating Officer since February 2017. Prior to joining the Company, Mr. Durso served as a consultant to the biopharmaceutical industry from September 2015 to February 2017. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as Senior Vice President, Chief Commercial Officer of the Global Diabetes Division from June 2011 to April 2015. From 2010 to 2011 Mr. Durso was Senior Vice President, Chief Commercial Officer of Sanofi’s U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso earned his bachelor’s degree in marketing from the University of Notre Dame.- Jerome Durso自2017年2月起担任我们的首席运营官。在加入公司之前，Durso先生于2015年9月至2017年2月担任生物制药行业顾问。杜尔索先生的大部分职业生涯都在赛诺菲（Sanofi）度过，赛诺菲是一家全球性制药公司，他最近于2011年6月至2015年4月担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。杜索先生在圣母大学获得市场营销学士学位。
- Jerome Durso has served as our Chief Operating Officer since February 2017. Prior to joining the Company, Mr. Durso served as a consultant to the biopharmaceutical industry from September 2015 to February 2017. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as Senior Vice President, Chief Commercial Officer of the Global Diabetes Division from June 2011 to April 2015. From 2010 to 2011 Mr. Durso was Senior Vice President, Chief Commercial Officer of Sanofi’s U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso earned his bachelor’s degree in marketing from the University of Notre Dame.
- David Ford
David Ford自2017年5月起担任我们的首席人力资源官。在加入赛诺菲之前，福特先生在赛诺菲工作了近15年，最近于2016年1月至2017年5月担任赛诺菲健赞全球业务部Vice President人力资源。在此之前，从2011年11月到2015年12月，福特先生担任赛诺菲北美业务的Vice President人力资源。Ford先生于2002年加入制药行业，担任Sanofi-Synthelabo的英国和爱尔兰共和国人力资源总监。Ford先生拥有法国枫丹白露欧洲工商管理学院（INSEAD）工商管理硕士学位。
David Ford has served as our Chief Human Resources Officer since May 2017. Prior to joining the Company, Mr. Ford spent nearly 15 years at Sanofi, where he most recently served as Vice President Human Resources for the Sanofi Genzyme global business unit from January 2016 to May 2017. Prior to that role, from November 2011 through December 2015 Mr. Ford served as Vice President Human Resources for the Sanofi North American businesses. Mr. Ford joined the pharmaceutical industry in 2002 as the HR Director - United Kingdom and Republic of Ireland for Sanofi-Synthelabo. Mr. Ford holds a master’s degree in business administration from INSEAD, Fontainebleau France.- David Ford自2017年5月起担任我们的首席人力资源官。在加入赛诺菲之前，福特先生在赛诺菲工作了近15年，最近于2016年1月至2017年5月担任赛诺菲健赞全球业务部Vice President人力资源。在此之前，从2011年11月到2015年12月，福特先生担任赛诺菲北美业务的Vice President人力资源。Ford先生于2002年加入制药行业，担任Sanofi-Synthelabo的英国和爱尔兰共和国人力资源总监。Ford先生拥有法国枫丹白露欧洲工商管理学院（INSEAD）工商管理硕士学位。
- David Ford has served as our Chief Human Resources Officer since May 2017. Prior to joining the Company, Mr. Ford spent nearly 15 years at Sanofi, where he most recently served as Vice President Human Resources for the Sanofi Genzyme global business unit from January 2016 to May 2017. Prior to that role, from November 2011 through December 2015 Mr. Ford served as Vice President Human Resources for the Sanofi North American businesses. Mr. Ford joined the pharmaceutical industry in 2002 as the HR Director - United Kingdom and Republic of Ireland for Sanofi-Synthelabo. Mr. Ford holds a master’s degree in business administration from INSEAD, Fontainebleau France.
- Jerome Durso
JeromeB.Durso自2017年2月起担任我们的首席运营官。他拥有近25年的在美国和国外的生命科学公司建立和领导商业和业务运营的经验。杜尔索的大部分职业生涯都在赛诺菲（Sanofi）度过。赛诺菲是一家全球性制药公司，他最近于2011年至2015年担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。Durso先生目前担任新泽西州萨默维尔Robert Wood Johnson University Hospital Somerset的顾问委员会成员。Durso先生在圣母大学（University of Notre Dame）获得营销学士学位。
Jerome Durso has served as Intercept Pharmaceuticals, Inc. chief operating officer since February 2017. He has nearly 25 years of experience in building and leading commercial and business operations at life sciences companies both in the United States and abroad. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as senior vice president, chief commercial officer of the global diabetes division from 2011 through 2015. From 2010 to 2011 Mr. Durso was senior vice president, chief commercial officer of Sanofi's U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso currently serves as an advisory board member of the Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey. Mr. Durso earned his bachelor degree in marketing from the University of Notre Dame.- JeromeB.Durso自2017年2月起担任我们的首席运营官。他拥有近25年的在美国和国外的生命科学公司建立和领导商业和业务运营的经验。杜尔索的大部分职业生涯都在赛诺菲（Sanofi）度过。赛诺菲是一家全球性制药公司，他最近于2011年至2015年担任赛诺菲全球糖尿病部门的高级副总裁，首席商务官。从2010年到2011年，杜尔索担任赛诺菲美国制药业务的高级副总裁，首席商务官。在此之前，自1993年首次加入赛诺菲以来，他担任过多个商业领导职务，在业务部门和品牌管理、市场营销与销售方面的责任越来越大。Durso先生目前担任新泽西州萨默维尔Robert Wood Johnson University Hospital Somerset的顾问委员会成员。Durso先生在圣母大学（University of Notre Dame）获得营销学士学位。
- Jerome Durso has served as Intercept Pharmaceuticals, Inc. chief operating officer since February 2017. He has nearly 25 years of experience in building and leading commercial and business operations at life sciences companies both in the United States and abroad. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as senior vice president, chief commercial officer of the global diabetes division from 2011 through 2015. From 2010 to 2011 Mr. Durso was senior vice president, chief commercial officer of Sanofi's U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso currently serves as an advisory board member of the Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey. Mr. Durso earned his bachelor degree in marketing from the University of Notre Dame.
- Andrew Saik
Andrew Saik自2019年3月15日起担任PDS的首席财务官兼董事。Saik先生最近担任Edge Therapeutics，Inc.的首席财务官，自2017年10月起领导IR职能并创建业务开发职能以帮助他发展公司。 Saik先生管理公司的外部信息，并帮助准备其主要资产的商业化。在加入Edge之前，Saik先生于2015年8月担任Vertice Pharma，LLC的首席财务官，负责管理一项3亿美元的承诺，为一家知名私募股权公司的收购提供资金。此前，他曾担任Auxilium Pharmaceuticals，Inc.的首席财务官，从2014年8月至2015年4月，他帮助领导执行Auxilium的增长战略并执行了一项价值7500万美元的成本削减计划，在期限贷款上购买了价值5000万美元的手风琴以确保流动性虽然重组并通过谈判达成了最终协议，以每股33.25美元的价格从17.51美元起售出该公司，导致股价在六个月内上涨85美元。 2013年2月至2014年8月，Saik先生担任Endo Health Solutions，Inc.的财务和财务高级副总裁，负责内部和外部报告，并购交易的全球整合，现金管理，债务融资和风险管理。在Endo任职期间，他帮助完成了对Paladin Labs的收购，并将3B美元的债务重组为新的公司结构。在加入Endo之前，Saik先生曾在Valeant Pharmaceuticals International担任高级财务管理职务，担任高级副总裁，财务和特种药剂业务首席财务官。在Valeant，他还负责$ 3B专业制药业务，他积极管理商业，制造和研发业务。他拥有南加州大学的工商管理硕士学位和加州大学洛杉矶分校的文学学士学位。
Andrew Saik is Menlo Therapeutics Inc.’s Chief Financial Officer and Treasurer. He previously served as the Chief Financial Officer and a director of PDS Biotechnology Corporation “PDS”, a clinical stage immuno-oncology company, from March 2019 until March 2020. Prior to joining PDS, Mr. Saik served as the Chief Financial Officer of Edge Therapeutics, Inc. (“Edge”) from October 2017 until its merger with PDS in March 2019. Prior to joining Edge, Mr. Saik served as CFO at Vertice Pharma, LLC from August 2015 until July 2017 and at Auxilium Pharmaceuticals, Inc. from August 2014 to April 2015. From February 2013 to August 2014 Mr. Saik was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc. (“Endo”). Prior to Endo, Mr. Saik served in senior financial management roles with increasing responsibility at Valeant Pharmaceuticals International, including Senior Vice President, Finance and CFO of the Specialty Pharmaceuticals Business. Mr. Saik holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.- Andrew Saik自2019年3月15日起担任PDS的首席财务官兼董事。Saik先生最近担任Edge Therapeutics，Inc.的首席财务官，自2017年10月起领导IR职能并创建业务开发职能以帮助他发展公司。 Saik先生管理公司的外部信息，并帮助准备其主要资产的商业化。在加入Edge之前，Saik先生于2015年8月担任Vertice Pharma，LLC的首席财务官，负责管理一项3亿美元的承诺，为一家知名私募股权公司的收购提供资金。此前，他曾担任Auxilium Pharmaceuticals，Inc.的首席财务官，从2014年8月至2015年4月，他帮助领导执行Auxilium的增长战略并执行了一项价值7500万美元的成本削减计划，在期限贷款上购买了价值5000万美元的手风琴以确保流动性虽然重组并通过谈判达成了最终协议，以每股33.25美元的价格从17.51美元起售出该公司，导致股价在六个月内上涨85美元。 2013年2月至2014年8月，Saik先生担任Endo Health Solutions，Inc.的财务和财务高级副总裁，负责内部和外部报告，并购交易的全球整合，现金管理，债务融资和风险管理。在Endo任职期间，他帮助完成了对Paladin Labs的收购，并将3B美元的债务重组为新的公司结构。在加入Endo之前，Saik先生曾在Valeant Pharmaceuticals International担任高级财务管理职务，担任高级副总裁，财务和特种药剂业务首席财务官。在Valeant，他还负责$ 3B专业制药业务，他积极管理商业，制造和研发业务。他拥有南加州大学的工商管理硕士学位和加州大学洛杉矶分校的文学学士学位。
- Andrew Saik is Menlo Therapeutics Inc.’s Chief Financial Officer and Treasurer. He previously served as the Chief Financial Officer and a director of PDS Biotechnology Corporation “PDS”, a clinical stage immuno-oncology company, from March 2019 until March 2020. Prior to joining PDS, Mr. Saik served as the Chief Financial Officer of Edge Therapeutics, Inc. (“Edge”) from October 2017 until its merger with PDS in March 2019. Prior to joining Edge, Mr. Saik served as CFO at Vertice Pharma, LLC from August 2015 until July 2017 and at Auxilium Pharmaceuticals, Inc. from August 2014 to April 2015. From February 2013 to August 2014 Mr. Saik was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc. (“Endo”). Prior to Endo, Mr. Saik served in senior financial management roles with increasing responsibility at Valeant Pharmaceuticals International, including Senior Vice President, Finance and CFO of the Specialty Pharmaceuticals Business. Mr. Saik holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.
- Andrew Saik
Andrew Saik，自2021年6月起担任Intercept Pharmaceuticals, Inc.TERM1首席财务官。Saik先生拥有20多年的生物制药金融经验，曾在多家公司担任管理职务。从2020年到2021年，Saik先生担任VYNE Therapeutics Inc.的首席财务官，在那里他帮助建立了公司在美国的财务部门，重新谈判了债务义务，为公司提供了更高的财务灵活性，并帮助筹集了超过1.35亿美元的资金来为运营提供资金。2017年至2020年，担任PDS Biotechnology公司（前身为Edge Therapeutics，Inc.）的首席财务官。2015年至2017年，任Vertice Pharma，LLC首席财务官。2014年至2015年，他担任Auxilium Pharmaceuticals, Inc.的首席财务官，2013年至2014年，他在Endo Health Solutions Inc.担任高级副总裁、财务和财务主管，在那里他帮助完成了对Paladin Labs的收购，并将30亿美元的债务重组为新的公司结构。2001年至2012年，他在Valeant Pharmaceuticals International担任高级财务管理职务。Saik先生拥有南加州大学的工商管理硕士学位和加州大学洛杉矶分校的文学学士学位。
Andrew Saik,has served as Intercept Pharmaceuticals, Inc. Chief Financial Officer since June 2021. Mr. Saik has more than 20 years of biopharmaceutical finance experience and has served in management positions in several companies. From 2020 to 2021, Mr. Saik was CFO of Vyne Therapeutics Inc., where he was instrumental in building out the company's finance department in the United States, renegotiated debt obligations to provide the company with enhanced financial flexibility, and helped raise over $135 million to fund operations. From 2017 to 2020, he was CFO of PDS Biotechnology Corporation (formerly Edge Therapeutics, Inc.). From 2015 to 2017, he was CFO of Vertice Pharma, LLC. From 2014 to 2015, he was CFO of Auxilium Pharmaceuticals, Inc. From 2013 to 2014, he was SVP, Finance and Treasurer at Endo Health Solutions Inc., where he helped complete the acquisition of Paladin Labs and restructured $3 billion of debt into a new corporate structure. From 2001 to 2012, he served in senior financial management roles at Valeant Pharmaceuticals International. Mr. Saik holds an M.B.A. from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.- Andrew Saik，自2021年6月起担任Intercept Pharmaceuticals, Inc.TERM1首席财务官。Saik先生拥有20多年的生物制药金融经验，曾在多家公司担任管理职务。从2020年到2021年，Saik先生担任VYNE Therapeutics Inc.的首席财务官，在那里他帮助建立了公司在美国的财务部门，重新谈判了债务义务，为公司提供了更高的财务灵活性，并帮助筹集了超过1.35亿美元的资金来为运营提供资金。2017年至2020年，担任PDS Biotechnology公司（前身为Edge Therapeutics，Inc.）的首席财务官。2015年至2017年，任Vertice Pharma，LLC首席财务官。2014年至2015年，他担任Auxilium Pharmaceuticals, Inc.的首席财务官，2013年至2014年，他在Endo Health Solutions Inc.担任高级副总裁、财务和财务主管，在那里他帮助完成了对Paladin Labs的收购，并将30亿美元的债务重组为新的公司结构。2001年至2012年，他在Valeant Pharmaceuticals International担任高级财务管理职务。Saik先生拥有南加州大学的工商管理硕士学位和加州大学洛杉矶分校的文学学士学位。
- Andrew Saik,has served as Intercept Pharmaceuticals, Inc. Chief Financial Officer since June 2021. Mr. Saik has more than 20 years of biopharmaceutical finance experience and has served in management positions in several companies. From 2020 to 2021, Mr. Saik was CFO of Vyne Therapeutics Inc., where he was instrumental in building out the company's finance department in the United States, renegotiated debt obligations to provide the company with enhanced financial flexibility, and helped raise over $135 million to fund operations. From 2017 to 2020, he was CFO of PDS Biotechnology Corporation (formerly Edge Therapeutics, Inc.). From 2015 to 2017, he was CFO of Vertice Pharma, LLC. From 2014 to 2015, he was CFO of Auxilium Pharmaceuticals, Inc. From 2013 to 2014, he was SVP, Finance and Treasurer at Endo Health Solutions Inc., where he helped complete the acquisition of Paladin Labs and restructured $3 billion of debt into a new corporate structure. From 2001 to 2012, he served in senior financial management roles at Valeant Pharmaceuticals International. Mr. Saik holds an M.B.A. from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.
- M. Michelle Berrey
M. Michelle Berrey，自2021年6月起担任Intercept Pharmaceuticals, Inc.研发总裁兼首席医疗官。Berrey博士最近于2012年至2019年担任Chimerix的总裁兼首席执行官，该公司的重点是免疫功能低下宿主的病毒感染。2007年至2012年，她在Pharmasset担任首席医疗官，在Sovaldi （索非布韦）治疗丙型肝炎的开发过程中发挥了关键作用。Berrey博士的药物开发职业生涯始于葛兰素惠康，随后是葛兰素史克。她曾在GW/GSK担任多个职务，最终担任病毒疾病、临床药理学和发现医学副总裁。在GW/GSK任职期间，她负责治疗HIV、肝炎病毒和肝纤维化的化合物的早期开发。自2021年3月以来，Berrey博士一直是Ocean Biomedical, Inc.的董事会成员，该公司于2023年2月根据特殊目的收购公司合并而上市。Berrey博士在佐治亚州医学院——奥古斯塔大学获得医学博士学位，并在埃默里大学获得公共卫生硕士学位。她在UNC Chapel Hill完成了内科住院医师实习，并在西雅图的UW完成了传染病研究金，在那里她的研究重点是HIV的传播、病毒库的早期建立以及急性感染期间早期抗病毒治疗的潜力。
M. Michelle Berrey,has served as Intercept Pharmaceuticals, Inc. President of Research & Development and Chief Medical Officer since June 2021. Dr. Berrey was most recently President and Chief Executive Officer at Chimerix from 2012 to 2019 where the focus was on viral infections in immunocompromised hosts. From 2007 to 2012, she served as Chief Medical Officer at Pharmasset, where she played a critical role in the development of Sovaldi (sofosbuvir) for treatment of hepatitis C. Dr. Berrey began her career in drug development at Glaxo Wellcome and then GlaxoSmithKline. She served in multiple roles at GW/GSK, eventually serving as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine. During her time at GW/GSK, she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses, and hepatic fibrosis. Since March 2021, Dr. Berrey has been on the board of directors of Ocean Biomedical, Inc., which in February 2023 became publicly traded pursuant to a special purpose acquisition company merger. Dr. Berrey received her M.D. from the Medical College of Georgia—Augusta University, and a Master of Public Health from Emory University. She completed her internal medicine residency at UNC Chapel Hill and a fellowship in Infectious Diseases at UW in Seattle, where her research focused on transmission of HIV, early establishment of the viral reservoir, and the potential for early antiviral therapy during acute infection.- M. Michelle Berrey，自2021年6月起担任Intercept Pharmaceuticals, Inc.研发总裁兼首席医疗官。Berrey博士最近于2012年至2019年担任Chimerix的总裁兼首席执行官，该公司的重点是免疫功能低下宿主的病毒感染。2007年至2012年，她在Pharmasset担任首席医疗官，在Sovaldi （索非布韦）治疗丙型肝炎的开发过程中发挥了关键作用。Berrey博士的药物开发职业生涯始于葛兰素惠康，随后是葛兰素史克。她曾在GW/GSK担任多个职务，最终担任病毒疾病、临床药理学和发现医学副总裁。在GW/GSK任职期间，她负责治疗HIV、肝炎病毒和肝纤维化的化合物的早期开发。自2021年3月以来，Berrey博士一直是Ocean Biomedical, Inc.的董事会成员，该公司于2023年2月根据特殊目的收购公司合并而上市。Berrey博士在佐治亚州医学院——奥古斯塔大学获得医学博士学位，并在埃默里大学获得公共卫生硕士学位。她在UNC Chapel Hill完成了内科住院医师实习，并在西雅图的UW完成了传染病研究金，在那里她的研究重点是HIV的传播、病毒库的早期建立以及急性感染期间早期抗病毒治疗的潜力。
- M. Michelle Berrey,has served as Intercept Pharmaceuticals, Inc. President of Research & Development and Chief Medical Officer since June 2021. Dr. Berrey was most recently President and Chief Executive Officer at Chimerix from 2012 to 2019 where the focus was on viral infections in immunocompromised hosts. From 2007 to 2012, she served as Chief Medical Officer at Pharmasset, where she played a critical role in the development of Sovaldi (sofosbuvir) for treatment of hepatitis C. Dr. Berrey began her career in drug development at Glaxo Wellcome and then GlaxoSmithKline. She served in multiple roles at GW/GSK, eventually serving as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine. During her time at GW/GSK, she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses, and hepatic fibrosis. Since March 2021, Dr. Berrey has been on the board of directors of Ocean Biomedical, Inc., which in February 2023 became publicly traded pursuant to a special purpose acquisition company merger. Dr. Berrey received her M.D. from the Medical College of Georgia—Augusta University, and a Master of Public Health from Emory University. She completed her internal medicine residency at UNC Chapel Hill and a fellowship in Infectious Diseases at UW in Seattle, where her research focused on transmission of HIV, early establishment of the viral reservoir, and the potential for early antiviral therapy during acute infection.
- Linda Richardson
Linda Richardson，自2021年2月起担任Intercept Pharmaceuticals, Inc.首席商务官。Richardson女士拥有30多年的商业战略、销售、营销经验。2018年至2021年，她担任Intercept Pharmaceuticals, Inc.高级副总裁兼Intercept Pharmaceuticals, Inc.胆汁淤积项目负责人。2013年至2018年，她曾任职于Chimerix, Inc.，最终担任首席战略和商务官一职，负责监督市场营销、市场准入和报销、市场研究和分析、预测、供应链和分销策略、商业运营、产品传播以及销售。从2008年到2013年，Richardson女士在赛诺菲担任越来越重要的商业领导职务，担任副总裁并领导该公司的全球GLP-1糖尿病特许经营权。在加入赛诺菲之前，Richardson女士在Reliant Pharmaceuticals和葛兰素史克都担任过越来越重要的职务，包括市场营销副总裁。Richardson女士被PM360评为制药行业“精英100”奖获得者，被医疗保健女企业家协会评为“新星”，并被PharmaVOICE评为“生命科学领域最具启发性的100位人物”。Richardson女士拥有宾夕法尼亚大学的英语学士学位。
Linda Richardson,has served as Intercept Pharmaceuticals, Inc. Chief Commercial Officer since February 2021. Ms. Richardson has more than 30 years of commercial strategy, sales, and marketing experience. From 2018 to 2021, she served as Intercept Pharmaceuticals, Inc. SVP and Head of Intercept Pharmaceuticals, Inc. Cholestasis Program. From 2013 to 2018, she worked at Chimerix, Inc., where she ultimately held the role of Chief Strategy and Commercial Officer, overseeing marketing, market access and reimbursement, market research and analytics, forecasting, supply chain and distribution strategies, commercial operations, product communications, and sales. From 2008 to 2013, Ms. Richardson held commercial leadership roles of increasing responsibility at Sanofi, where she was a Vice President and led the company's global GLP-1 diabetes franchise. Prior to joining Sanofi, Ms. Richardson held roles of increasing responsibility at both Reliant Pharmaceuticals and GlaxoSmithKline, including Vice President of Marketing. Ms. Richardson has been recognized by PM360 as an "ELITE 100" award winner in the pharmaceutical industry, by the Healthcare Businesswomen's Association as a "Rising Star," and by PharmaVOICE as one of its "Top 100 Most Inspiring People in Life Sciences." Ms. Richardson holds a bachelor's degree in English from the University of Pennsylvania.- Linda Richardson，自2021年2月起担任Intercept Pharmaceuticals, Inc.首席商务官。Richardson女士拥有30多年的商业战略、销售、营销经验。2018年至2021年，她担任Intercept Pharmaceuticals, Inc.高级副总裁兼Intercept Pharmaceuticals, Inc.胆汁淤积项目负责人。2013年至2018年，她曾任职于Chimerix, Inc.，最终担任首席战略和商务官一职，负责监督市场营销、市场准入和报销、市场研究和分析、预测、供应链和分销策略、商业运营、产品传播以及销售。从2008年到2013年，Richardson女士在赛诺菲担任越来越重要的商业领导职务，担任副总裁并领导该公司的全球GLP-1糖尿病特许经营权。在加入赛诺菲之前，Richardson女士在Reliant Pharmaceuticals和葛兰素史克都担任过越来越重要的职务，包括市场营销副总裁。Richardson女士被PM360评为制药行业“精英100”奖获得者，被医疗保健女企业家协会评为“新星”，并被PharmaVOICE评为“生命科学领域最具启发性的100位人物”。Richardson女士拥有宾夕法尼亚大学的英语学士学位。
- Linda Richardson,has served as Intercept Pharmaceuticals, Inc. Chief Commercial Officer since February 2021. Ms. Richardson has more than 30 years of commercial strategy, sales, and marketing experience. From 2018 to 2021, she served as Intercept Pharmaceuticals, Inc. SVP and Head of Intercept Pharmaceuticals, Inc. Cholestasis Program. From 2013 to 2018, she worked at Chimerix, Inc., where she ultimately held the role of Chief Strategy and Commercial Officer, overseeing marketing, market access and reimbursement, market research and analytics, forecasting, supply chain and distribution strategies, commercial operations, product communications, and sales. From 2008 to 2013, Ms. Richardson held commercial leadership roles of increasing responsibility at Sanofi, where she was a Vice President and led the company's global GLP-1 diabetes franchise. Prior to joining Sanofi, Ms. Richardson held roles of increasing responsibility at both Reliant Pharmaceuticals and GlaxoSmithKline, including Vice President of Marketing. Ms. Richardson has been recognized by PM360 as an "ELITE 100" award winner in the pharmaceutical industry, by the Healthcare Businesswomen's Association as a "Rising Star," and by PharmaVOICE as one of its "Top 100 Most Inspiring People in Life Sciences." Ms. Richardson holds a bachelor's degree in English from the University of Pennsylvania.
- Jared Freedberg
Jared Freedberg，自2021年2月起担任Intercept Pharmaceuticals, Inc.总法律顾问。Freedberg先生为公司带来了作为高级律师和制药行业高级业务发展主管的跨学科经验。2018年至2020年，他担任Immunomedics, Inc.的总法律顾问和公司秘书。2016年至2018年，他曾在马林克罗制药担任特种仿制药运营部门总法律顾问以及法律、业务发展和许可副总裁。从2001年到2016年，他在科文司担任越来越重要的职务，包括副总裁兼副总法律顾问，从2014年到2016年，担任业务发展和战略副总裁，担任Covance全球执行领导团队成员。在他职业生涯的早期，弗里德伯格曾在私人诊所工作。他拥有杜克大学法学院的法学博士学位，以及宾夕法尼亚大学的学士学位。
Jared Freedberg,Jared Freedberg,has served as Intercept Pharmaceuticals, Inc. General Counsel since February 2021.From 2018 to 2020, he was General Counsel and Corporate Secretary of Immunomedics, Inc. From 2016 to 2018, he was General Counsel, Specialty Generics Operating Division, and VP, Legal, Business Development and Licensing, at Mallinckrodt Pharmaceuticals. From 2001 to 2016, he held positions of increasing responsibility at Covance Inc., including Vice President and Associate General Counsel, and, from 2014 to 2016, VP for Business Development and Strategy, in which capacity he was a member of Covance's Global Executive Leadership Team. Earlier in his career, Mr. Freedberg was in private practice. He holds a J.D. from Duke University School of Law, and a bachelor's degree from the University of Pennsylvania.- Jared Freedberg，自2021年2月起担任Intercept Pharmaceuticals, Inc.总法律顾问。Freedberg先生为公司带来了作为高级律师和制药行业高级业务发展主管的跨学科经验。2018年至2020年，他担任Immunomedics, Inc.的总法律顾问和公司秘书。2016年至2018年，他曾在马林克罗制药担任特种仿制药运营部门总法律顾问以及法律、业务发展和许可副总裁。从2001年到2016年，他在科文司担任越来越重要的职务，包括副总裁兼副总法律顾问，从2014年到2016年，担任业务发展和战略副总裁，担任Covance全球执行领导团队成员。在他职业生涯的早期，弗里德伯格曾在私人诊所工作。他拥有杜克大学法学院的法学博士学位，以及宾夕法尼亚大学的学士学位。
- Jared Freedberg,Jared Freedberg,has served as Intercept Pharmaceuticals, Inc. General Counsel since February 2021.From 2018 to 2020, he was General Counsel and Corporate Secretary of Immunomedics, Inc. From 2016 to 2018, he was General Counsel, Specialty Generics Operating Division, and VP, Legal, Business Development and Licensing, at Mallinckrodt Pharmaceuticals. From 2001 to 2016, he held positions of increasing responsibility at Covance Inc., including Vice President and Associate General Counsel, and, from 2014 to 2016, VP for Business Development and Strategy, in which capacity he was a member of Covance's Global Executive Leadership Team. Earlier in his career, Mr. Freedberg was in private practice. He holds a J.D. from Duke University School of Law, and a bachelor's degree from the University of Pennsylvania.
- Rocco Venezia
Rocco Venezia，自2021年3月起担任Intercept Pharmaceuticals, Inc.首席会计官兼财务主管，为工作带来20多年的相关财务、会计经验。此前，自2016年起担任Intercept Pharmaceuticals, Inc.公司控制人，在公司财务和会计部门从发展阶段过渡到完全一体化的商业机构期间，领导公司财务和会计部门的扩张。在加入公司之前，Venezia先生于2013年至2016年在Ikaria，Inc.（现为马林克罗制药的一部分）担任公司助理财务总监，在那里他领导会计和财务团队进行运营和系统转型。从2000年到2013年，Venezia先生在毕马威会计师事务所和Arthur Andersen担任越来越多的职责，在那里他领导了多个行业的跨国审计、交易和尽职调查业务。Venezia先生还在毕马威会计师事务所的专业实践部工作了三年，在那里他为复杂的技术会计、合规事务和审计方法方面的项目团队提供支持。Venezia先生拥有Kean大学会计学学士学位，是新泽西州和纽约州的注册会计师。
Rocco Venezia,has served as Intercept Pharmaceuticals, Inc. Chief Accounting Officer and Treasurer since March 2021,he served as Intercept Pharmaceuticals, Inc. Corporate Controller since 2016, where he led the expansion of the Company's finance and accounting department during its transition from development-stage to a fully integrated commercial organization. Before he joined the Company, Mr. Venezia was the Assistant Corporate Controller at Ikaria, Inc., now part of Mallinckrodt Pharmaceuticals, from 2013 to 2016, where he led the accounting and finance team through operational and system transformations. From 2000 to 2013, Mr. Venezia held roles of increasing responsibility at KPMG LLP and Arthur Andersen, where he led multinational audits, transactions and due diligence engagements across several industries. Mr. Venezia also spent three years at KPMG LLP's Department of Professional Practice where he supported engagement teams on complex technical accounting, compliance matters and audit methodology. Mr. Venezia holds a bachelor's degree in accounting from Kean University and is a certified public accountant in New Jersey and New York.- Rocco Venezia，自2021年3月起担任Intercept Pharmaceuticals, Inc.首席会计官兼财务主管，为工作带来20多年的相关财务、会计经验。此前，自2016年起担任Intercept Pharmaceuticals, Inc.公司控制人，在公司财务和会计部门从发展阶段过渡到完全一体化的商业机构期间，领导公司财务和会计部门的扩张。在加入公司之前，Venezia先生于2013年至2016年在Ikaria，Inc.（现为马林克罗制药的一部分）担任公司助理财务总监，在那里他领导会计和财务团队进行运营和系统转型。从2000年到2013年，Venezia先生在毕马威会计师事务所和Arthur Andersen担任越来越多的职责，在那里他领导了多个行业的跨国审计、交易和尽职调查业务。Venezia先生还在毕马威会计师事务所的专业实践部工作了三年，在那里他为复杂的技术会计、合规事务和审计方法方面的项目团队提供支持。Venezia先生拥有Kean大学会计学学士学位，是新泽西州和纽约州的注册会计师。
- Rocco Venezia,has served as Intercept Pharmaceuticals, Inc. Chief Accounting Officer and Treasurer since March 2021,he served as Intercept Pharmaceuticals, Inc. Corporate Controller since 2016, where he led the expansion of the Company's finance and accounting department during its transition from development-stage to a fully integrated commercial organization. Before he joined the Company, Mr. Venezia was the Assistant Corporate Controller at Ikaria, Inc., now part of Mallinckrodt Pharmaceuticals, from 2013 to 2016, where he led the accounting and finance team through operational and system transformations. From 2000 to 2013, Mr. Venezia held roles of increasing responsibility at KPMG LLP and Arthur Andersen, where he led multinational audits, transactions and due diligence engagements across several industries. Mr. Venezia also spent three years at KPMG LLP's Department of Professional Practice where he supported engagement teams on complex technical accounting, compliance matters and audit methodology. Mr. Venezia holds a bachelor's degree in accounting from Kean University and is a certified public accountant in New Jersey and New York.
- M. Michelle Berrey
M. Michelle Berrey自2014年4月起担任Chimerix, Inc.总裁兼首席执行官，并自2014年6月起担任Chimerix, Inc.董事会成员。此外，Berrey博士自2012年11月被任命为首席医疗官以来一直担任该职务，直到2014年9月新的首席医疗官，W. Garrett Nichols接任。2007年1月至2012年1月，Berrey博士在Pharmasset, Inc.担任首席医疗官，Pharmasset, Inc.专注于开发用于治疗丙型肝炎的核苷酸类似物。2004年1月至2007年1月，Berrey博士在GlaxoSmithKline担任病毒疾病、临床药理学与发现医学副总裁，负责用于治疗HIV、肝炎病毒和肝纤维化的化合物的早期开发。Berrey博士获得了Emory大学的英语学士学位、Georgia医学院的医学博士学位和Emory大学的公共卫生硕士学位。Berrey博士在North Carolina大学Chapel Hill分校完成了内科实习和住院医师实习，并在西雅图华盛顿大学担任传染病高级研究员，在那里她进行了HIV传播和急性HIV感染方面的研究。
M. Michelle Berrey has served as Chimerix, Inc. President and Chief Executive Officer since April 2014 and has been a member of Chimerix, Inc. Board of Directors since June 2014. From January 2007 to January 2012 Dr. Berrey served as Chief Medical Officer at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C. From January 2004 to January 2007 Dr. Berrey served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey earned a B.A. in English from Emory University, an M.D. from the Medical College of Georgia and an M.P.H. from Emory University. Dr. Berrey completed her internship and residency in Internal Medicine at the University of North Carolina, Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection.- M. Michelle Berrey自2014年4月起担任Chimerix, Inc.总裁兼首席执行官，并自2014年6月起担任Chimerix, Inc.董事会成员。此外，Berrey博士自2012年11月被任命为首席医疗官以来一直担任该职务，直到2014年9月新的首席医疗官，W. Garrett Nichols接任。2007年1月至2012年1月，Berrey博士在Pharmasset, Inc.担任首席医疗官，Pharmasset, Inc.专注于开发用于治疗丙型肝炎的核苷酸类似物。2004年1月至2007年1月，Berrey博士在GlaxoSmithKline担任病毒疾病、临床药理学与发现医学副总裁，负责用于治疗HIV、肝炎病毒和肝纤维化的化合物的早期开发。Berrey博士获得了Emory大学的英语学士学位、Georgia医学院的医学博士学位和Emory大学的公共卫生硕士学位。Berrey博士在North Carolina大学Chapel Hill分校完成了内科实习和住院医师实习，并在西雅图华盛顿大学担任传染病高级研究员，在那里她进行了HIV传播和急性HIV感染方面的研究。
- M. Michelle Berrey has served as Chimerix, Inc. President and Chief Executive Officer since April 2014 and has been a member of Chimerix, Inc. Board of Directors since June 2014. From January 2007 to January 2012 Dr. Berrey served as Chief Medical Officer at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C. From January 2004 to January 2007 Dr. Berrey served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey earned a B.A. in English from Emory University, an M.D. from the Medical College of Georgia and an M.P.H. from Emory University. Dr. Berrey completed her internship and residency in Internal Medicine at the University of North Carolina, Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection.
- Linda Richardson
Linda Richardson自2014年1月以来一直担任Chimerix, Inc.的首席财务官。在加入公司之前，从2011年12月她担任Global lixisenatide franchise（位于Sanofi S.A的一家特许经营全球制药公司）的副经理。从2008年9月到2011年11月担任美国Sanofi S.A.市场副总经理，同eplivanserin, Auvi-Q 和 MultaqAuvi-Q Multaq共同负责领导各种营销活动。从2006年10月到2008年6月她担任 Reliant Pharmaceuticals, Inc.公司的市场营销副经理。Richardson女士拥有宾夕法尼亚大学的英语学士学位。
Linda Richardson,has served as Intercept Pharmaceuticals, Inc. Chief Commercial Officer since February 2021. Ms. Richardson has more than 30 years of commercial strategy, sales, and marketing experience. From 2018 to 2021, she served as Intercept Pharmaceuticals, Inc. SVP and Head of Intercept Pharmaceuticals, Inc. Cholestasis Program. From 2013 to 2018, she worked at Chimerix, Inc., where she ultimately held the role of Chief Strategy and Commercial Officer, overseeing marketing, market access and reimbursement, market research and analytics, forecasting, supply chain and distribution strategies, commercial operations, product communications, and sales. From 2008 to 2013, Ms. Richardson held commercial leadership roles of increasing responsibility at Sanofi, where she was a Vice President and led the company's global GLP-1 diabetes franchise. Prior to joining Sanofi, Ms. Richardson held roles of increasing responsibility at both Reliant Pharmaceuticals and GlaxoSmithKline, including Vice President of Marketing. Ms. Richardson has been recognized by PM360 as an "ELITE 100" award winner in the pharmaceutical industry, by the Healthcare Businesswomen's Association as a "Rising Star," and by PharmaVOICE as one of its "Top 100 Most Inspiring People in Life Sciences." Ms. Richardson holds a bachelor's degree in English from the University of Pennsylvania.- Linda Richardson自2014年1月以来一直担任Chimerix, Inc.的首席财务官。在加入公司之前，从2011年12月她担任Global lixisenatide franchise（位于Sanofi S.A的一家特许经营全球制药公司）的副经理。从2008年9月到2011年11月担任美国Sanofi S.A.市场副总经理，同eplivanserin, Auvi-Q 和 MultaqAuvi-Q Multaq共同负责领导各种营销活动。从2006年10月到2008年6月她担任 Reliant Pharmaceuticals, Inc.公司的市场营销副经理。Richardson女士拥有宾夕法尼亚大学的英语学士学位。
- Linda Richardson,has served as Intercept Pharmaceuticals, Inc. Chief Commercial Officer since February 2021. Ms. Richardson has more than 30 years of commercial strategy, sales, and marketing experience. From 2018 to 2021, she served as Intercept Pharmaceuticals, Inc. SVP and Head of Intercept Pharmaceuticals, Inc. Cholestasis Program. From 2013 to 2018, she worked at Chimerix, Inc., where she ultimately held the role of Chief Strategy and Commercial Officer, overseeing marketing, market access and reimbursement, market research and analytics, forecasting, supply chain and distribution strategies, commercial operations, product communications, and sales. From 2008 to 2013, Ms. Richardson held commercial leadership roles of increasing responsibility at Sanofi, where she was a Vice President and led the company's global GLP-1 diabetes franchise. Prior to joining Sanofi, Ms. Richardson held roles of increasing responsibility at both Reliant Pharmaceuticals and GlaxoSmithKline, including Vice President of Marketing. Ms. Richardson has been recognized by PM360 as an "ELITE 100" award winner in the pharmaceutical industry, by the Healthcare Businesswomen's Association as a "Rising Star," and by PharmaVOICE as one of its "Top 100 Most Inspiring People in Life Sciences." Ms. Richardson holds a bachelor's degree in English from the University of Pennsylvania.